top of page
AEnB2Uq_HIiXrr6Uye1O7aZ5edPEz3r8ICmVEm8k9WIpa8GnDYiuQwMuSahKqwy82Yi7yRhU9ZSJdY5rzHIdRqOnNl
ABOUT CAMURUS

Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.  

SORENTO CLINICAL TRIAL

The SORENTO study is seeking adult volunteers with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NET). The study drug, CAM2029, is a long-acting investigational formulation of octreotide provided in either a ready-to-use syringe or pre-filled pen that can be administered at home by you or a caregiver. Learn more and find out if you could be part of this opportunity to test a potential new treatment option here. 

The study drug, tests, examinations, and study-related medical care are provided at no cost to qualified study participants. Reimbursement for certain study-related expenses such as travel may be also available.

Sorento Clinical Trial  - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Criteria for Participation

  • To take part, you must:

  • Be 18 years of age or older

  • Have advanced (unresectable and/or metastatic) GEP-NET

  • Not have GEP-NET that has spread to the brain or central nervous system or progressed after previous treatment (refractory)

  • Not have been treated with long-acting SSAs for longer than 6 months

  • Other criteria will be reviewed to determine if you may participate in the study.

 

The study drug, tests, examinations, and study-related medical care are provided at no cost to qualified study participants. Reimbursement for certain study-related expenses such as travel may be available.

 

Do you have any questions? Contact Camurus at medicalinfo@camurus.com.

This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by LACNETS. Talk to your medical team about your individual care and treatment. 

bottom of page